Skip to main
BCAX
BCAX logo

BCAX Stock Forecast & Price Target

BCAX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Bicara Therapeutics' stock outlook appears positive due to the superior efficacy of its ficerafusp alfa therapy, which demonstrates a meaningful enhancement over existing treatments, specifically achieving an objective response rate (ORR) that exceeds those of Keytruda and its combination therapies. The clinical data reveals a median progression-free survival (mPFS) of 9.9 months and a median overall survival (mOS) of 21.3 months when ficerafusp alfa is combined with Keytruda, suggesting significant improvements in patient outcomes compared to existing therapies, which report lower mOS rates. These promising clinical results position Bicara Therapeutics favorably in the competitive landscape of biopharmaceuticals, particularly for patients with solid tumors.

Bears say

Bicara Therapeutics Inc reported a net loss of $0.50 per share for the second quarter of 2025, consistent with prior estimates, indicating ongoing financial challenges. The company faces significant risks, including potential negative clinical results for its lead drug ficerafusp alfa, delays in trial advancements, and difficulties in obtaining timely regulatory approvals, which could hinder future growth. Additionally, long-term dilution risk and competitive pressures from other bispecific therapies in development further contribute to a negative financial outlook for the company.

BCAX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicara Therapeutics Inc (BCAX) Forecast

Analysts have given BCAX a Buy based on their latest research and market trends.

According to 5 analysts, BCAX has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicara Therapeutics Inc (BCAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.